Penarth, United Kingdom
The company's offerings encompass a wide range of diagnostic technologies and biotechnology solutions. In the point-of-care sector, EKF develops and manufactures in-vitro diagnostics (IVD) that deliver quick and accurate results, allowing healthcare professionals to make rapid decisions. This includes products related to diabetes care, such as glucose monitoring systems and associated supplies, as well as products for measuring hemoglobin levels.
EKF's presence extends to over 120 countries, providing the necessary solutions to support better health and wellness worldwide. The company's last investment was a Venture Round investment at 01 June 2010, with the investor being HYGEA VCT PLC.
In the life sciences sector, EKF develops and supplies diagnostic and therapeutic enzymes, proteins, reagents, and other bio-materials used in research, biotechnology, and pharmaceutical industries. They also offer precision fermentation, custom bioprocessing, and contract manufacturing services, along with products for detecting ketones for clinical applications. Overall, EKF Diagnostics presents promising potential for investors looking to enter the health care and manufacturing industries, with a strong focus on point-of-care technology and life sciences applications.
